Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft

Transplant Immunology

Volumn 25, Issue 1, 2011, Pages 72-76

  Pavlova, Yelena ^a   Viklicky, Ondrej ^a   Slatinska, Janka ^a   Bürgelova, Marcela ^a   Süsal, Caner ^b   Skibova, Jelena ^a   Honsová, Eva ^a   Striz, Ilja ^a   Kolesar, Libor ^a   Slavcev, Antonij ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antibody mediated rejection; Hepatocyte growth factor; Soluble CD30

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; BELATACEPT; BIOLOGICAL MARKER; CD30 ANTIGEN; CYCLOSPORIN; EVEROLIMUS; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SCATTER FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETRANSPLANTATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME;

AGED; ANTIBODY FORMATION; ANTIGENS, CD30; BIOLOGICAL MARKERS; FEMALE; GRAFT REJECTION; HEPATOCYTE GROWTH FACTOR; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959654937     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2011.02.003     Document Type: Article

References (28)

1. Regele H., Bohmig G.A., Habicht A., Gollowitzer D., Schillinger M., Rockenschaub S., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002, 13:2371-2380.
2. Colvin R.B., Smith R.N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005, 5:807-817.
3. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056.
4. Pelzl S., Opelz G., Wiesel M., Schnülle P., Schönemann C., Döhler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73:3-6.
5. Susal C., Pelzl S., Dohler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13:1650-1656.
6. Slavcev A., Lacha J., Honsova E., Sajdlova H., Lodererova A., Vitko S., et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005, 14:117-121.
7. Rodriguez L.M., Paris S.C., Arbelaez M., Cotes J.M., Susa C., Torres Y., et al. Kidney graft recipients with pretransplantation HLA class I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007, 68:652-660.
8. Horie R., Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998, 10:457-470.
9. Schlaf G., Altermann W.W., Rothhoff A., Seliger B. Soluble CD30 serum level-an adequate marker for allograft rejection of solid organs?. Histol Histopathol 2007, 22:1269-1279.
10. Rajakariar R., Jivanji N., Varagunam M., Rafiq M., Gupta A., Sheaff M., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005, 5:1922-1925.
11. Vaidya S., Partlow D., Barnes T., Thomas P., Gugliuzza K. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. Clin Transplant 2006, 20:461-464.
12. Vaidya S., Partlow D., Barnes T., Gugliuzza K. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006, 82:1606-1609.
13. Weimer R., Süsal C., Yildiz S., Staak A., Pelzl S., Renner F., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006, 6:1865-1874.
14. Slavcev A., Honsova E., Lodererova A., Pavlova Y., Sajdlova H., Vitko S., et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol 2007, 18:22-27.
15. Zwirska-Korczala K., Zakliczynski M., Berdowska A., Zembala M., Jochem J., Gajewska K. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation. J Heart Lung Transplant 2005, 24:411-415.
16. Mahmoud K., Opelz G., Pelzl S., Daniel V., Sommerer C., Zeier M., et al. Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation 2007, 83:1035-1040.
17. Pavlova Y.A., Malek I., Honsova E., Netuka I., Sochman J., Lodererova A.., et al. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients. Tissue Antigens 2010, 76:380-386.
18. Jin Y.P., Jindra P.T., Gong K.W., Lepin E.J., Reed E.F. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005, 79:S19-S21.
19. Miyazawa K. Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor. FEBS 2010, 277:2208-2214.
20. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
21. Racusen L.C., Halloran P.F., Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004, 4:1562-1566.
22. Solez K., Colvin R.B., Racusen L.C., Haas M., Sis B., Mengel M., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008, 8:753-760.
23. Pelzl S., Opelz G., Daniel V., Wiesel M., Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75:421-423.
24. Langan L.L., Park L.P., Hughes T.L., Irish A., Luxton G., Witt C.S., et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7:847-856.
25. Heinemann F.M., Rebmann V., Witzke O., Philipp T., Broelsch C.E., Grosse-Wilde H. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 2007, 83:706-711.
26. Yoshimura R., Chargui J., Watanabe Y., Kasai S., Hase T., Ohyama A., et al. Can recombinant hepatocyte growth factor suppress acute renal rejection?. Transplant Proc 2001, 33:2322-2323.
27. Yoshimura R., Watanabe Y., Kasai S., et al. Hepatocyte growth factor (HGF) as a rapid diagnostic marker and its potential in the prevention of acute renal rejection. Transpl Int 2002, 15:156-162.
28. Susal C., Dohler B., Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol 2009, 70:569-573.